The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia.

Volume: 7, Issue: 1, Pages: 12308 - 12308
Published: Jul 25, 2016
Abstract
Tumour hypoxia renders cancer cells resistant to cancer therapy, resulting in markedly worse clinical outcomes. To find clinical candidate compounds that reduce hypoxia in tumours, we conduct a high-throughput screen for oxygen consumption rate (OCR) reduction and identify a number of drugs with this property. For this study we focus on the anti-malarial, atovaquone. Atovaquone rapidly decreases the OCR by more than 80% in a wide range of cancer...
Paper Details
Title
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia.
Published Date
Jul 25, 2016
Volume
7
Issue
1
Pages
12308 - 12308
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.